证券代码：000952 证券简称：广济药业 公告编号：2022-049 湖北广济药业股份有限公司 关于参加 2022 年湖北辖区上市公司投资者 集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： ●会议召开时间：2021 年 6 月 16 日（星期四）14:00-16:00 ●会议召开方式：网络远程方式 一、说明会类型 为进一步加强湖北广济药业股份有限公司（以下简称"公司"）与投资者互 动交流，根据湖北省上市公司协会《关于举办 2022 年湖北辖区上市公司投资者 集体接待日暨 2021 年度业绩说明会活动的通知》（鄂上协发[2022]10 号），公 司将于 2021 年 6 月 16 日下午参加由湖北证监局、湖北省上市公司协会、深圳市 全景网络有限公司联合举办的"2022 年湖北辖区上市公司投资者集体接待日暨 2021 年度业绩说明会活动"，通过网络与投资者互动交流。 二、活动召开的时间、方式 召开时间：2021 年 6 月 16 日（星期四）14:00-16:00 会议方式：网络远程方式，通过"全景•路演天下"（http:/ ...

Revenue and Profitability - The company's revenue for Q1 2022 was CNY 178,873,451.83, representing a 1.45% increase compared to CNY 176,325,538.59 in the same period last year[4] - Net profit attributable to shareholders decreased by 39.62% to CNY 8,356,171.56 from CNY 13,838,265.84 year-on-year[4] - Total operating revenue for Q1 2022 was CNY 178,873,451.83, a slight increase from CNY 176,325,538.59 in Q1 2021, representing a growth of approximately 1.4%[22] - Net profit for Q1 2022 was CNY 7,655,581.24, down from CNY 12,935,440.72 in Q1 2021, reflecting a decrease of approximately 40.5%[24] - The company's operating profit for Q1 2022 was CNY 8,728,468.35, compared to CNY 17,897,295.19 in the same period last year, a decline of about 51.2%[23] - The company reported a total comprehensive income of CNY 7,647,988.93 for Q1 2022, down from CNY 12,935,440.72 in Q1 2021, reflecting a decrease of approximately 40.5%[24] Cash Flow and Financial Position - The net cash flow from operating activities was negative at CNY -329,051.98, a decline of 101.15% compared to CNY 28,496,950.04 in the previous year[10] - Cash flow from operating activities in Q1 2022 was CNY -329,051.98, a significant decline compared to CNY 28,496,950.04 in Q1 2021[26] - The net cash flow from investment activities was -46,697,286.75, compared to -23,944,091.49 in the previous year, indicating a significant increase in cash outflow for investments[27] - Cash inflow from financing activities totaled 334,443,480.00, up from 102,651,520.00 in the same period last year, reflecting a strong increase in financing efforts[27] - The net cash flow from financing activities was 162,240,812.11, compared to -28,468,667.35 in the previous year, showing a positive turnaround in financing[27] - The total cash and cash equivalents at the end of the period reached 318,188,097.11, an increase from 265,723,641.72 in the previous year[27] - The company received cash from borrowings amounting to 275,000,000.00, significantly higher than 102,651,520.00 in the previous year, indicating increased leverage[27] - The cash outflow for the acquisition of fixed assets, intangible assets, and other long-term assets was 46,998,496.47, compared to 24,183,491.49 in the previous year, reflecting increased capital expenditures[27] - The cash paid for debt repayment was 167,250,000.00, compared to 126,316,855.83 in the previous year, indicating a higher focus on debt management[27] Assets and Liabilities - Total assets increased by 13.06% to CNY 2,316,525,859.76 from CNY 2,048,896,426.54 at the end of the previous year[4] - The total liabilities as of March 31, 2022, were RMB 1,200,000,000, reflecting an increase from the previous year[19] - Total liabilities as of Q1 2022 were CNY 858,073,922.87, compared to CNY 598,092,478.58 in the previous year, indicating an increase of approximately 43.5%[23] - The company's long-term borrowings rose dramatically by 521.04% to CNY 213,950,000.00, reflecting increased financing needs for operations[8] - The company’s short-term borrowings increased to RMB 255,000,000 from RMB 236,279,188.89, showing a rise of approximately 7.3%[19] Inventory and Receivables - The company’s inventory increased by 32.49% to CNY 218,384,674.56, attributed to higher procurement of pharmaceutical distribution and trading goods[8] - Accounts receivable rose to RMB 193,938,139.72 from RMB 182,981,957.15, indicating an increase of approximately 6.4%[18] - The company reported a significant increase in other receivables, which rose to RMB 13,739,352.64 from RMB 9,764,746.75, indicating an increase of about 40.3%[18] Government Support and Incentives - The company received government subsidies amounting to CNY 6,383,687.72, which is a 96.98% increase compared to the previous year[10] - A total of 8.649 million restricted stock units were granted to 118 eligible participants at a price of RMB 3.52 per share as part of the incentive plan approved by the Hubei Provincial Government[14] Research and Development - The company plans to implement a mixed reform strategy by introducing a research and development team to enhance its capabilities in drug formulation and production[16] - The company established a subsidiary, Hubei Guangji Pharmaceutical Technology Co., Ltd., to strengthen its R&D capabilities and product development platform[16] - Research and development expenses for Q1 2022 amounted to CNY 9,185,119.75, an increase from CNY 7,506,265.22 in the previous year, representing a growth of about 22.4%[23] Miscellaneous - The impact of exchange rate changes on cash and cash equivalents was -98,645.94, contrasting with a positive impact of 101,256.70 in the previous year[27] - The first quarter report was not audited, which may affect the reliability of the financial data presented[28]

Financial Performance - The company's operating revenue for 2021 was CNY 837,106,649.29, representing a 21.64% increase compared to CNY 688,169,323.69 in 2020[19] - The net profit attributable to shareholders for 2021 was CNY 110,107,173.86, a 47.50% increase from CNY 74,647,103.88 in 2020[19] - The net profit after deducting non-recurring gains and losses was CNY 65,639,729.59, up 69.85% from CNY 38,645,048.49 in 2020[19] - The basic earnings per share for 2021 was CNY 0.3201, an increase of 43.41% compared to CNY 0.2232 in 2020[19] - The total operating revenue for 2021 was ¥837,106,649.29, representing a year-on-year increase of 21.64% compared to ¥688,169,323.69 in 2020[53] - The pharmaceutical manufacturing sector contributed ¥696,943,606.45, accounting for 83.26% of total revenue, with a growth of 4.26% from the previous year[54] - The gross profit margin for the pharmaceutical manufacturing sector was 42.99%, reflecting a 1.42% increase from the previous year[56] - Domestic sales reached ¥531,339,455.87, a 27.17% increase from ¥417,833,793.04 in 2020, while international sales were ¥305,767,193.42, up 13.11%[54] Cash Flow and Investments - The net cash flow from operating activities for 2021 was CNY 75,907,303.46, a decrease of 36.42% from CNY 119,381,525.89 in 2020[19] - The operating cash flow decreased by 36.42% to 75.91 million yuan, primarily due to increased tax payments and cash outflows for goods and services[46] - The company achieved a net cash flow from operating activities of ¥75,907,303.46 in 2021, a decrease of 36.42% compared to ¥119,381,525.89 in 2020[74] - The total amount of raised funds is CNY 358.10 million, with CNY 65.26 million used during the reporting period and CNY 224.65 million used cumulatively[87] - The company has a remaining unutilized raised fund amount of CNY 139.72 million, which is currently held in a special account[87] Research and Development - The company completed 23 patent applications in 2021, including 5 invention patents and 18 utility model patents, and received a total of 90 domestic and international patent authorizations by the end of the reporting period[43] - The R&D expenses increased by 34.28% to 52.06 million yuan, driven by investments in optimizing fermentation processes for vitamin B2 and heat-resistant strains[46] - The number of R&D personnel rose to 203 in 2021, a 3.57% increase from 196 in 2020, with a notable increase in the number of bachelor's degree holders by 31.82%[74] - The company is advancing several key R&D projects, including the production of high-end antibiotics and the optimization of Vitamin B2 production processes, aiming for market competitiveness[69] - The company is actively developing multiple products in its R&D pipeline, indicating a focus on innovation and market responsiveness[101] Market and Industry Dynamics - The pharmaceutical industry is experiencing intensified competition due to policy reforms and market dynamics, pushing companies towards innovation as a core growth driver[30] - The vitamin industry has shown cyclical characteristics, with significant price fluctuations and profit variations since 2007, impacting the company's strategic planning[34] - The market is currently in a state of oversupply, with strong head companies expanding production capacity, which may affect pricing and profitability in the future[34] - The company faces significant market risks in the vitamin B sector due to oversupply and intense competition, leading to prolonged low prices for its main products VB2 and VB6[100] Governance and Compliance - The company has implemented a robust governance structure, ensuring compliance with legal and regulatory requirements, and maintaining transparency with shareholders[105] - The board of directors consists of 9 members, including 3 independent directors, ensuring a diverse and compliant governance framework[106] - The company has established effective communication channels with investors, including the use of online platforms for engagement and information dissemination[107] - The company adheres to strict information disclosure practices, ensuring all shareholders have equal access to relevant information[108] - The company has a clear asset ownership structure, with full control over its assets and no instances of asset misappropriation by the controlling shareholder[109] Employee and Social Responsibility - The company reported a total of 1,317 employees at the end of the reporting period, with 786 in production, 62 in sales, 207 in technical roles, 27 in finance, and 235 in administration[141] - The company has a training plan in place to enhance employee skills and knowledge, aiming for continuous improvement and mutual benefits for the company and its employees[144] - The company actively participates in community governance and public health initiatives, receiving recognition from local governments[177] - The company contributed 200,000 RMB to the Mengzhou Charity Association and raised an additional 15,000 RMB from employees during the "99 Charity Day" event[177] Environmental Management - The company is classified as a key pollutant discharge unit, with specific wastewater discharge standards met, including COD and ammonia nitrogen levels[162] - The company has established various board committees, including the audit committee and strategic management committee, to enhance governance practices[159] - The company has implemented measures to enhance employee knowledge of environmental management systems, including ISO 14001 training[172] - The company has successfully passed expert reviews for its clean production initiatives[165] Future Plans and Strategies - The company plans to enhance its market position through new product launches and improvements in existing product lines, targeting both domestic and international markets[69] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[50] - The company is committed to sustainable development, aligning economic, environmental, and social benefits[176] - The company is actively pursuing opportunities for mergers and acquisitions to enhance its competitive position in the market[120]

Financial Performance - The company's operating revenue for Q3 2021 was ¥153,025,444.18, a decrease of 11.06% compared to the same period last year[3] - Net profit attributable to shareholders was ¥14,463,917.06, down 49.90% year-on-year, while net profit after deducting non-recurring gains and losses was ¥13,131,191.41, a decrease of 52.88%[3] - The company's basic earnings per share for Q3 2021 were ¥0.0420, a decrease of 51.16% compared to the same period last year[3] - Total operating revenue for the current period is ¥476,334,358.27, a decrease of 7.1% compared to ¥512,925,865.11 in the previous period[19] - Net profit for the current period increased to ¥70,762,725.31, up 59.3% from ¥44,369,986.06 in the previous period[20] - Operating profit rose to ¥82,547,084.84, an increase of 16.5% compared to ¥70,831,626.07 in the previous period[20] - Total comprehensive income for the current period was ¥70,728,188.49, compared to ¥44,395,546.45 in the previous period, reflecting a significant increase[21] - Basic and diluted earnings per share improved to ¥0.2156 from ¥0.1443, representing a growth of 49.4%[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,029,161,380.53, reflecting a 2.51% increase from the end of the previous year[3] - The company's current assets totaled RMB 732,838,471.74, compared to RMB 702,078,108.43 at the end of 2020, indicating an increase of about 4.4%[16][18] - Accounts receivable rose to RMB 113,378,501.30 from RMB 104,126,189.56, representing an increase of approximately 8.7% year-over-year[16][18] - Inventory increased significantly to RMB 205,156,089.94, up from RMB 163,573,855.70, marking a growth of around 25.5%[16][18] - Short-term borrowings increased to RMB 246,510,580.00 from RMB 203,636,855.83, which is an increase of approximately 21%[17][18] - Total liabilities decreased slightly to RMB 613,383,385.69 from RMB 613,748,833.05, showing a marginal decline of about 0.6%[18] Investment and Income - The company reported a significant increase in investment income, reaching ¥18,805,394.72, a rise of 771.08% year-on-year due to debt restructuring gains[9] - The company's long-term equity investments increased by 113.82% to ¥32,848,471.83, attributed to the net asset increase of its joint venture[8] - The long-term equity investment increased to RMB 32,848,471.83 from RMB 15,362,437.12, indicating a growth of approximately 113.5%[16][18] Expenses - The company experienced a 28.87% reduction in selling expenses, amounting to ¥15,582,715.46, due to changes in revenue recognition standards[8] - Total operating costs decreased to ¥419,085,867.85 from ¥448,296,054.86, reflecting a reduction of 6.5%[19] - Research and development expenses slightly decreased to ¥28,975,921.78 from ¥29,823,985.63, a decline of 2.8%[20] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥70,403,789.39, down 35.26% compared to the same period last year[9] - Cash flow from operating activities generated a net amount of ¥70,403,789.39, down 35.2% from ¥108,749,008.81 in the previous period[24] - Cash and cash equivalents at the end of the period totaled ¥312,683,285.79, a decrease from ¥318,945,914.90 in the previous period[25] - Investment activities resulted in a net cash outflow of ¥39,001,358.06, compared to a larger outflow of ¥195,503,465.94 in the previous period[25] Corporate Developments - The company announced a strategic cooperation agreement with China National Pharmaceutical Group Hubei Co., Ltd. in the field of raw materials and pharmaceutical formulations[13] - The completion date for the annual production of 1,000 tons of Vitamin B12 project has been postponed to December 30, 2022[13] Shareholder Information - The total equity attributable to shareholders was ¥1,426,584,501.63, an increase of 3.90% from the previous year[4] - The number of ordinary shareholders at the end of the reporting period was 29,237[11] Reporting Standards - The third quarter report of Hubei Guangji Pharmaceutical Co., Ltd. is unaudited[27] - The new lease accounting standards were first implemented in 2021, with retrospective adjustments made to prior comparative data[27] - The board of directors announced the third quarter report on October 21, 2021[27]

湖北广济药业股份有限公司 2021 年半年度报告全文 湖北广济药业股份有限公司 2021 年半年度报告 2021 年 08 月 1 湖北广济药业股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人阮澍、主管会计工作负责人胡明峰及会计机构负责人(会计主管 人员)王琼声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的 实质承诺，敬请投资者注意投资风险。 公司已在本报告"第三节 管理层讨论与分析"中分析了公司未来发展可能 面临的风险因素和制定对策情况。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 6 | | 第三节 | 管理层讨论与分析 9 | | 第四节 | 公司治理 17 | | ...

湖北广济药业股份有限公司 2021 年第一季度报告全文 湖北广济药业股份有限公司 2021 年第一季度报告 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人阮澍、主管会计工作负责人胡明峰及会计机构负责人(会计主管 人员)王琼声明：保证季度报告中财务报表的真实、准确、完整。 2 湖北广济药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 2021 年 04 月 1 湖北广济药业股份有限公司 2021 年第一季度报告全文 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 176,325,538.59 | 133,421,305.86 | 32.16% | | 归属于上市公司股东的净利润（元） | 13,838,265.84 ...

Financial Performance - The company's operating revenue for 2020 was CNY 688,169,323, a decrease of 5.90% compared to CNY 731,340,517 in 2019[18]. - The net profit attributable to shareholders was CNY 74,647,103.8, down 14.14% from CNY 86,943,194.9 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 38,645,048.4, a decline of 24.26% from CNY 51,022,090.0 in 2019[18]. - The cash flow from operating activities was CNY 119,381,525, representing a decrease of 17.21% compared to CNY 144,200,478 in 2019[18]. - Basic earnings per share were CNY 0.2232, down 21.44% from CNY 0.3500 in the previous year[18]. - The total operating revenue for 2020 was ¥688,169,323.69, a decrease of 5.90% compared to ¥731,340,517.94 in 2019[51]. - The net profit attributable to shareholders was 74.65 million, down 14.14% year-on-year[38]. - Operating profit was 96.84 million, reflecting a slight decrease of 2.06% compared to the previous year[39]. - The net profit for 2019 was CNY 20,066,663.1, with a profit distribution ratio of 23.08%[108]. Assets and Equity - The total assets at the end of 2020 were CNY 1,979,438,635.76, an increase of 12.05% from CNY 1,766,508,421.42 in 2019[18]. - The net assets attributable to shareholders increased by 42.97% to CNY 1,373,075,553.04 from CNY 960,377,290.08 in 2019[18]. - The company's total share capital as of December 31, 2020, was 346,995,039 shares, after deducting 2,995,100 shares repurchased[109]. - The company's available distributable profit for 2020 was CNY 697,653,593.31[109]. Revenue Breakdown - The pharmaceutical manufacturing sector accounted for 100% of the total operating revenue, with raw material products contributing ¥539,923,362.29 (78.46%) and formulation products contributing ¥109,027,978.59 (15.84%)[51]. - Domestic revenue decreased by 10.55% to ¥417,833,793.04, while international revenue increased by 2.31% to ¥270,335,530.65[51]. - The sales volume of high-content riboflavin products increased by 22% year-on-year, while the sales of riboflavin phosphate sodium products rose by 16%[44]. Research and Development - The company has established a biotechnology research institute to enhance R&D capabilities in "biological synthesis" and "chemical synthesis" fields[28]. - The company holds 27 domestic and international patents, including 16 for its main product, riboflavin, demonstrating a strong focus on innovation[33]. - R&D expenses decreased by 27.90% to 38.77 million, primarily due to the completion of certain product upgrades[39]. - The company completed clinical BE experiments for two new products: Amino Acid Tablets and Entecavir Tablets, and produced qualified products for Pyridoxal Phosphate and VB12 projects[61]. Investment and Financing - The company successfully raised 364 million through a private placement, marking a significant milestone in capital market operations[38]. - The company raised ¥859,362,484.77 through financing activities, a 36.05% increase compared to the previous year[63]. - The total amount of raised funds in 2020 was CNY 35,810.3 million, with CNY 15,939.3 million utilized so far, representing 44.52% of the total[79]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 0.6 per 10 shares, totaling approximately 20.64 million CNY, representing a cash dividend payout ratio of 27.65%[103]. - For the 2019 fiscal year, the cash dividend was 0.70 CNY per 10 shares, totaling approximately 20.07 million CNY, with a payout ratio of 23.08%[103]. Compliance and Governance - The company did not disclose any significant undisclosed information during the investor communications, ensuring compliance with regulations[100]. - The company adheres to legal regulations to protect shareholder and creditor rights, enhancing investor recognition[144]. - There were no significant accounting errors requiring retrospective restatement during the reporting period[119]. Environmental and Social Responsibility - The company donated a total of 2 million yuan to the Wuxue municipal government to support COVID-19 prevention efforts[149]. - The company has invested 63.44 million yuan in poverty alleviation projects, focusing on agricultural and tourism development[155]. - The company has actively engaged in environmental protection initiatives, upgrading technology and eliminating high-energy-consuming equipment[148]. - The company completed a waste gas treatment project with a total investment of approximately 2 million yuan, which has a capacity of 20,000 m³/h[161]. Risk Management - The company faces risks from industry policy changes, including drug procurement and medical insurance reforms, which may impact its operations[95]. - Fluctuations in raw material prices pose a risk to the company's cost structure, prompting it to strengthen market monitoring and strategic reserves[95]. - The company acknowledges the risk of increased R&D costs due to stricter regulations, leading to potential delays or failures in drug development[96].

湖北广济药业股份有限公司 2020 年第三季度报告全文 湖北广济药业股份有限公司 2020 年第三季度报告 2020 年 10 月 1 湖北广济药业股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人安靖、主管会计工作负责人胡明峰及会计机构负责人(会计主管 人员)王琼声明：保证季度报告中财务报表的真实、准确、完整。 2 湖北广济药业股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 | | 本报告期末 | | | 上年度末 | | | 本报告期末比上年 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 度末增减 | | | | | | 调整前 | | 调整后 | | 调整后 | ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥340,870,457.41, a decrease of 6.74% compared to ¥365,490,654.33 in the same period last year[19]. - The net profit attributable to shareholders was ¥18,946,666.34, down 69.83% from ¥62,791,960.92 year-on-year[19]. - Basic earnings per share decreased to ¥0.0583, down 76.87% from ¥0.252 in the same period last year[19]. - Total operating revenue decreased by 6.74% to CNY 340,870,457.41 compared to CNY 365,490,654.33 in the same period last year[43]. - The total profit for the first half of 2020 was CNY 23.77 million, a decline of 69.1% from CNY 77.00 million in the same period of 2019[146]. - The company's operating profit was CNY 35.04 million, significantly lower than CNY 75.83 million in the previous year, reflecting a decrease of 53.8%[146]. - The total comprehensive income for the first half of 2020 was CNY 45,177.83 million[173]. - The net profit attributable to the owners of the parent company was 0.99 billion yuan, a decrease of 9.3% year-on-year[164]. Cash Flow and Financial Position - The net cash flow from operating activities increased significantly to ¥67,268,057.39, representing a 570.91% increase compared to ¥10,026,316.95 in the previous year[19]. - The net increase in cash and cash equivalents reached CNY 300,062,722.08, reflecting a 360.44% increase from CNY 65,168,241.37 in the previous year[41]. - The company's cash and cash equivalents amounted to CNY 483,715,278.63, significantly up from CNY 183,652,556.55 at the end of 2019, indicating an increase of about 163.36%[136]. - The cash inflow from financing activities reached CNY 753,384,891.51, significantly higher than CNY 286,012,000.00 in the previous year, marking an increase of about 163.5%[157]. - The cash outflow for financing activities totaled CNY 469,509,675.79, up from CNY 197,058,397.13 in the same period last year, representing an increase of approximately 138.5%[157]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,061,213,724.05, an increase of 16.68% from ¥1,766,508,421.42 at the end of the previous year[19]. - The company's total assets reached 1.431 billion, showcasing growth in asset management[171]. - Total liabilities decreased to CNY 749,255,533.68, down from CNY 802,209,888.60 at the end of 2019, indicating a reduction in financial leverage[139]. - The company's equity attributable to shareholders rose to CNY 1,317,371,238.59, an increase of 37.3% from CNY 960,377,290.08[139]. Operational Challenges and Strategies - The company faced a significant decline in net profit due to various operational challenges during the reporting period[19]. - The company has identified potential risks and formulated countermeasures for future development[5]. - The company is focusing on enhancing production capacity and sales of its main products, particularly vitamins B2 and B6, which saw growth despite market challenges[36]. - The company is implementing a refined management strategy to optimize production processes and reduce costs for its main products[37]. - The company is actively pursuing market expansion through strategic investments and potential acquisitions to accelerate growth[38]. Research and Development - The company has obtained 27 domestic and international patents, including 16 for its main product, riboflavin, and has achieved consistency evaluation for vitamin B6 and B2 tablets[32]. - The company is advancing its R&D efforts, with ongoing projects for new products like the green organic VB2 and the antibiotic replacement product[38]. - Research and development investment decreased by 6.36% to CNY 18,963,405.94 compared to CNY 20,251,829.38 in the previous year[41]. - The R&D expenses for the period were 0.18 billion yuan, accounting for approximately 6.5% of total revenue[163]. Environmental Responsibility - The company has upgraded its wastewater treatment system and added multiple RTO facilities to enhance its waste treatment capabilities, reflecting its commitment to environmental responsibility[31]. - Hubei Guangji Pharmaceutical Co., Ltd. reported that all environmental protection facilities are operating normally with no exceedance of pollutant emissions[88]. - The company conducted monitoring of environmental pollutants in the first and second quarters of 2020, in compliance with its pollution discharge permit[96]. - The company has initiated clean production verification work to enhance environmental sustainability[89]. Shareholder and Market Activities - The company successfully raised ¥364 million through a private placement of shares, marking its first such issuance in 20 years[38]. - The company issued 37,956,203 new shares through a private placement and distributed 57,333,323 bonus shares to shareholders[111]. - The total number of shares after the issuance and bonus shares is 346,995,039[111]. - The largest shareholder, Hubei Changjiang Industrial Investment Group Co., Ltd., held 25.24% of the shares, totaling 87,592,065 shares[118]. Legal and Compliance - The company is involved in a significant lawsuit with a claim amount of 5,552,493 CNY, which has not yet formed a liability provision[69]. - The company has no media scrutiny issues during the reporting period[70]. - There are no penalties or rectifications reported during the reporting period[71]. - The financial report for the first half of 2020 was not audited[134].

湖北广济药业股份有限公司 2020 年第一季度报告 2020 年 04 月 1 湖北广济药业股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 湖北广济药业股份有限公司 2020 年第一季度报告全文 所有董事均已出席了审议本次季报的董事会会议。 公司负责人安靖、主管会计工作负责人胡明峰及会计机构负责人(会计主管 人员)王琼声明：保证季度报告中财务报表的真实、准确、完整。 2 湖北广济药业股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 133,421,305.86 | 180,917,718.37 | -26.25% | | 归属于上市公司股东的净利润（元） | -13,243,999.3 ...